(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Remain Informed about the Most recent Open Record Extra Offers - 26 Top of the line Lodgings All over The Planet, Which One Do You Concur With
- 3Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- 4Manual for Famous Beverages 2024
- 5Working out at the airport? Some fliers can already smell the sweat.
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
- Finding the Force of Mentorship: Self-awareness Through Direction
- Best Veggie lover Dinner: What's Your Plant-Based Pick?
- Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- Russia downs 16 drones heading for Moscow, mayor says
- The Force of Systems administration: Individual Examples of overcoming adversity
- Defense Minister Katz moves to extend IDF service to 36 months
- Medicine doesn’t just have ‘conscientious objectors’ − there are ‘conscientious providers,’ too
- Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
